echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > U.S. FDA approves Pfizer vaccine to prevent tick-borne encephalitis

    U.S. FDA approves Pfizer vaccine to prevent tick-borne encephalitis

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pfizer recently announced that the US FDA has approved TicoVac (tick-borne encephalitis vaccine) for the prevention of tick-borne encephalitis (TBE) in individuals over 1 year old


    TBE is a viral infection of the brain and spine, which can be transmitted to humans through the bite of a virus-infected tick


    Pfizer’s TBE vaccine is marketed in Europe under the trade names of FSME-immune and TicoVac, and in the United States under the trade name of TicoVac, developed using a "seed" virus similar to the TBE virus found in nature


    Clinical trials evaluated the safety and immunogenicity of TicoVac in two age groups (1-15 years and >16 years)


    Reference materials:

    [1] US FDA Approves TICOVAC™, Pfizer's Tick-Borne Encephalitis (TBE) Vaccine.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.